Publication | Closed Access

A combined α7 nicotinic acetylcholine receptor agonist and monoamine reuptake inhibitor, NS9775, represents a novel profile with potential benefits in emotional and cognitive disturbances

Monoamine Reuptake InhibitorMolecular PharmacologyPotential BenefitsPsychiatryMedicinePsychotropic MedicationNicotineAffective NeurosciencePsychopharmacologyNeuropharmacologyNeuroscienceMood DisordersNovel ProfileSocial Sciences